Current Research in Triple-Negative Breast Cancer
Richard S. Finn, MD, discusses current research in triple-negative breast cancer
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).
Clinical Pearls:
- TNBC is an area of unmet need and is defined by the absence of a druggable target
- Researchers have studied Src inhibition and PARP inhibition in this space
- A new PARP inhibitor, BMN 673, looks particularly potent forBRCA-mutated breast cancer
- Patients withBRCA-mutated breast cancer are often triple negative
- There is still a need to better understand the biology of TNBC in order to bring the right drugs to these patients
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
